Risk of prostate cancer in low-dose aspirin users: A retrospective cohort study

International Journal of Cancer

Volumn 139, Issue 1, 2016, Pages 205-211

  Lapi, F ^a   Levi, M ^a,b   Simonetti, M ^a   Cancian, M ^c   Parretti, D ^c   Cricelli, I ^a   Sobrero, A ^d   Cricelli, C ^c  

^a Health Search   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Italian College of General Practitioners   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

low dose aspirin; prevention; prostate cancer

Indexed keywords

ACETYLSALICYLIC ACID; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFECT; DRUG EXPOSURE; DRUG USE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME VARIABLE; POPULATION RESEARCH; PRIORITY JOURNAL; PROPENSITY SCORE; PROSTATE CANCER; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY; RISK REDUCTION; SENSITIVITY ANALYSIS; TREATMENT DURATION; VERY ELDERLY; YOUNG ADULT; ADENOCARCINOMA; ADOLESCENT; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; RISK FACTOR;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84961267115     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30061     Document Type: Article

References (41)

1. Rothwell PM, Wilson M, Elwin C-E, et al., Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376: 1741-50.
2. Rothwell PM, Wilson M, Price JF, et al., Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379: 1591-601.
3. Algra AM, Rothwell PM., Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13: 518-27.
4. Reimers MS, Bastiaannet E, van Herk-Sukel MPP, et al., Aspirin use after diagnosis improves survival in older adults with colon cancer: a retrospective cohort study. J Am Geriatr Soc 2012; 60: 2232-6.
5. Langley RE., Clinical evidence for the use of aspirin in the treatment of cancer. Ecancermedicalscience 2013; 7: 297
6. Smith T, Elwood P, Keating C, et al., The Aspirin Foundation Scientific Conference: the history, the present state and the future of aspirin prophylaxis. Ecancermedicalscience 2014; 8: 388.
7. Bosetti C, Rosato V, Gallus S, et al., Aspirin and cancer risk: A quantitative review to 2011. Ann Oncol 2012; 23: 1403-15.
8. Mahmud SM, Franco EL, Aprikian AG., Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer 2010; 127: 1680-91.
9. Huang T, Yan Y, Guo Z, et al., Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies. Int Urol Nephrol 2014; 46: 1715-28.
10. Liu Y, Chen J-Q, Xie L, et al., Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. BMC Med 2014; 12: 55
11. Bosetti C, Rosato V, Gallus S, et al., Aspirin and prostate cancer prevention. Recent Results Cancer Res 2014; 202: 93-100.
12. Nordström T, Clements M, Karlsson R, et al., The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. Eur J Cancer 2015; 51: 725-33.
13. Bosetti C, Talamini R, Negri E, et al., Aspirin and the risk of prostate cancer. Eur J Cancer Prev 2006; 15: 43-5.
14. Menezes RJ, Swede H, Niles R, et al., Regular use of aspirin and prostate cancer risk (United States). Cancer Causes Control 2006; 17: 251-6.
15. Leitzmann MF, Stampfer MJ, Ma J, et al., Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002; 11: 1108-11.
16. McLean D, Williams D, Lamont S, Krueger H., Community-Based Prevention: Reducing the Risk of Cancer and Chronic Disease. University of Toronto, 2013.
17. Menotti A, Puddu PE., Coronary heart disease differences across Europe. J Cardiovasc Med 2013; 14: 767-72.
18. International Agency for Research on Cancer. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: [Internet]. Lyon, France: IARC CancerBase No. 112013.
19. Bianchini E, Brignoli O, Cricelli C, et al., VIII Report Health Search. Firenze: Anno 2013/2014, 2014.
20. Coloma PM, Valkhoff VE, Mazzaglia G, et al., Identification of acute myocardial infarction from electronic healthcare records using different disease coding systems: a validation study in three European countries. BMJ Open 2013; 3.
21. Mazzaglia G, Sessa E, Samani F., Use of Computerized General Practice Database for epidemiological studies in Italy: a comparative study with the official national statistics. J Epidemiol Commun Heal 2004; 58.
22. Sterrantino C, Trifirò G, Lapi F, et al., Burden of community-acquired pneumonia in Italian general practice. Eur Respir J 2013; 42: 1739-42. [cited 2015 Dec 10];:-.
23. Jacobs EJ, Rodriguez C, Mondul AM, et al., A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005; 97: 975-80.
24. Jacobs EJ, Thun MJ, Bain EB, et al., A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007; 99: 608-15.
25. Salinas CA, Kwon EM, FitzGerald LM, et al., Use of Aspirin and Other Nonsteroidal Antiinflammatory Medications in Relation to Prostate Cancer Risk. Am J Epidemiol 2010; 172: 578-90.
26. Bayer Corporation. Aspirin. Comprehensive prescribing information. Available at http://www.fda.gov/ohrms/dockets/ac/03/briefing/4012B1-03-Appd%201-Professional%20Labeling.pdf. Access on November 2015.
27. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2015. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2014.
28. Paganini-Hill A, Chao A, Ross RK, et al., Aspirin use and chronic diseases: a cohort study of the elderly. Bmj 1989; 299: 1247-50.
29. Yood MU, Campbell UB, Rothman KJ, et al., Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf 2007; 16: 961-8.
30. Psaty BM, Koepsell TD, et al., Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 1999; 47: 749-54.
31. Colotta F, Allavena P, Sica A, et al., Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073-81.
32. Roxburgh CSD, McMillan DC., Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010; 6: 149-63.
33. Bahig H, Taussky D, Delouya G, et al., Neutrophil count is associated with survival in localized prostate cancer. BMC Cancer 2015; 15: 594
34. Soumaoro LT, Uetake H, Higuchi T, et al., Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004; 10: 8465-71.
35. Gupta S, Srivastava M, Ahmad N, et al., Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42: 73-8.
36. Fujita H, Koshida K, Keller ET, et al., Cyclooxygenase-2 promotes prostate cancer progression. Prostate 2002; 53: 232-40.
37. Farmadati Italia. Available at: www.farmadati.it. Access on November 2015.
38. Cea Soriano L, Soriano-Gabarró M, García Rodríguez LA., Validation of low-dose aspirin prescription data in The Health Improvement Network: how much misclassification due to over-the-counter use? Pharmacoepidemiol Drug Saf, in press. Internet] [cited 2015 Dec 19];Available from: http://www.ncbi.nlm.nih.gov/pubmed/26660710
39. International Agency for Research on Cancer. EUCAN. Most frequent cancers in men. Italy: International Agency for Research on Cancer, 2012.
40. Moyad MA., Preventing aggressive prostate cancer with proven cardiovascular disease preventive methods. Asian J Androl 2015; 17: 874-7.
41. Brookhart MA, Wyss R, Layton JB, et al., Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes 2013; 6: 604-11.